[ CAS No. 166599-84-4 ] {[proInfo.proName]}

Name: 166599-84-4|Benzofuran-4-carboxylic acid|95%
Brand: Ambeed
SKU: A110181
Price: 29.0 USD
Availability: InStock
Rating: 94 (22 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 166599-84-4

Structure of 166599-84-4 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 166599-84-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 166599-84-4 ]

SDS Specification

Alternatived Products of [ 166599-84-4 ]

Product Details of [ 166599-84-4 ]

CAS No. :	166599-84-4	MDL No. :	MFCD10000600
Formula :	C₉H₆O₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	WFAPIZKLEVLUMX-UHFFFAOYSA-N
M.W :	162.14	Pubchem ID :	22324117
Synonyms :

Calculated chemistry of [ 166599-84-4 ]

Physicochemical Properties

Num. heavy atoms :	12
Num. arom. heavy atoms :	9
Fraction Csp3 :	0.0
Num. rotatable bonds :	1
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	43.17
TPSA :	50.44 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.98 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.5
Log Po/w (XLOGP3) :	1.85
Log Po/w (WLOGP) :	2.13
Log Po/w (MLOGP) :	1.08
Log Po/w (SILICOS-IT) :	1.75
Consensus Log Po/w :	1.66

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-2.5
Solubility :	0.513 mg/ml ; 0.00316 mol/l
Class :	Soluble
Log S (Ali) :	-2.53
Solubility :	0.478 mg/ml ; 0.00295 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.65
Solubility :	0.363 mg/ml ; 0.00224 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.18

Safety of [ 166599-84-4 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 166599-84-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 166599-84-4 ]
Downstream synthetic route of [ 166599-84-4 ]

[ 166599-84-4 ] Synthesis Path-Upstream 1~7

1
[ 41019-56-1 ]
[ 166599-84-4 ]

Yield	Reaction Conditions	Operation in experiment
99%	With water; lithium hydroxide In tetrahydrofuran; methanol at 20℃; for 16 h;	A solution of LiOH (1.44 g, 34.3 mmol) in water (20 mL) was added to a solution of 131 (2.02 g, 11.4 mmol) in THF (20mL) and MeOH (20 mL) and the solution was stirred at r.t. for 16 h and then evaporated. The residue was dissolved in water (50 mL) and acidified with cone. HC1 and the precipitate was filtered and dried to give 132 (1.83 g, 99percent). 1H NMR (DMSO-d₆) δ 13.10 (s, 1H), 8.14 (d, J = 2.1 Hz, 1H), 7.85-7.91 (m, 2H), 7.43 (t, J = 7.9 Hz, 1H), 7.33 (dd, J = 2.1, 1.0 Hz, 1H). Found: [M-H] = 161.1.
99%	Stage #1: With lithium hydroxide In tetrahydrofuran; methanol; water at 20℃; for 16 h; Stage #2: With hydrogenchloride In water	A solution of LiOH (1.44 g, 34.3 mmol) in water (20 mL) wasadded to a solution of the above ester (2.02 g, 11.4 mmol) in THF(20 mL) and MeOH (20 mL) and the solution was stirred at 20 Cfor 16 h and then evaporated. The residue was dissolved in water(50 mL) and acidified with conc. HCl and the precipitate was filteredand dried to give benzofuran-4-carboxylic acid (1.83 g,99percent). 1H NMR (DMSO d6) d 13.10 (s, 1H), 8.14 (d, J = 2.1 Hz, 1H),7.85–7.91 (m, 2H), 7.43 (t, J = 7.9 Hz, 1H), 7.33 (dd, J = 2.1, 1.0 Hz,1H). Found: [MH] = 161.1.

Reference： [1] Patent: WO2017/155909, 2017, A1, . Location in patent: Paragraph 0190
[2] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 8, p. 1797 - 1809
[3] Journal of Medicinal Chemistry, 1995, vol. 38, # 16, p. 3094 - 3105

2
[ 166599-85-5 ]
[ 166599-84-4 ]

Yield	Reaction Conditions	Operation in experiment
62%	Stage #1: for 5.46667 h; Heating / reflux Stage #2: With sodium hydroxide; water In toluene at 60℃; for 9 h; Stage #3: With hydrogenchloride In water at 2 - 14℃; for 14.5 h; Heating / reflux	A solution of Intermediate 10 in toluene (1 wt in 6.6 vol) was added to a refluxing mixture of p-toluenesulfonic acid (0.03 eq., 0.03 wt) in toluene (3.8 vol) over 43 minutes. The mixture was stirred under reflux for 33 minutes then solvent (1.1 vol) was withdrawn at 130 ⁰C jacket temperature under slightly reduced pressure (1000- 880 mbar). The mixture was further stirred at reflux. 4.25 hours after the addition of Intermediate 10 the mixture was cooled to 25 ⁰C. The mixture was filtered over silica gel (1.1 wt) that had been conditioned with toluene (4.1 vol). The silica plug was further washed with toluene (8.2 vol). The product containing fractions were combined (total volume 10.8 vol). Solvent (8.6 vol) was withdrawn at 80 ⁰C jacket temperature under reduced pressure. Toluene (0.6 vol) and 1.0 M NaOH (1.5 eq., 7.7 vol) was added and the two-phase mixture was stirred at 60 ⁰C for 9 hours. After cooling to 20 ⁰C the phases were separated and 32percent HCI (1.7 vol) was added at 2- 14°C to the aqueous phase. After addition of 9.4 vol toluene the mixture was stirred under reflux for 14.5 hours. The suspension was cooled to 20 ⁰C and THF (5.3 vol) was added. The phases were separated and the organic layer was washed two times with a mixture of 5.6 vol water and 0.6 vol THF. 10.3 vol of solvent was distilled off at 80 ⁰C jacket temperature and reduced pressure before 3.2 vol toluene was added. The mixture was refluxed for 33 minutes (ambient pressure), cooled to 0 ⁰C over 3 hours and stirred at that temperature for 2.5 days. The precipitate was filtered, dried for 2 hours in a stream of nitrogen and dried in a rotavap at 50 ⁰C to give the title compound as an off-white solid. Yield (percent theory): 62percent

Reference： [1] Patent: WO2009/34133, 2009, A1, . Location in patent: Page/Page column 18
[2] Journal of Medicinal Chemistry, 1995, vol. 38, # 16, p. 3094 - 3105

3
[ 79250-46-7 ]
[ 166599-84-4 ]

Reference： [1] Journal of Medicinal Chemistry, 1995, vol. 38, # 16, p. 3094 - 3105

4
[ 79950-39-3 ]
[ 166599-84-4 ]

Reference： [1] Journal of Medicinal Chemistry, 1995, vol. 38, # 16, p. 3094 - 3105

5
[ 177734-79-1 ]
[ 166599-84-4 ]

Reference： [1] Patent: WO2017/155909, 2017, A1,
[2] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 8, p. 1797 - 1809

6
[ 480-97-7 ]
[ 166599-84-4 ]

Reference： [1] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 8, p. 1797 - 1809

7
[ 166599-84-4 ]
[ 209256-42-8 ]

Reference： [1] Patent: EP1027043, 2004, B1,

[ 166599-84-4 ] Synthesis Path-Downstream 1~62

1
[ 41019-56-1 ]
[ 166599-84-4 ]

Yield	Reaction Conditions	Operation in experiment
99%	With water; lithium hydroxide; In tetrahydrofuran; methanol; at 20℃; for 16h;	A solution of LiOH (1.44 g, 34.3 mmol) in water (20 mL) was added to a solution of 131 (2.02 g, 11.4 mmol) in THF (20mL) and MeOH (20 mL) and the solution was stirred at r.t. for 16 h and then evaporated. The residue was dissolved in water (50 mL) and acidified with cone. HC1 and the precipitate was filtered and dried to give 132 (1.83 g, 99%). 1H NMR (DMSO-d6) delta 13.10 (s, 1H), 8.14 (d, J = 2.1 Hz, 1H), 7.85-7.91 (m, 2H), 7.43 (t, J = 7.9 Hz, 1H), 7.33 (dd, J = 2.1, 1.0 Hz, 1H). Found: [M-H] = 161.1.
99%		A solution of LiOH (1.44 g, 34.3 mmol) in water (20 mL) wasadded to a solution of the above ester (2.02 g, 11.4 mmol) in THF(20 mL) and MeOH (20 mL) and the solution was stirred at 20 Cfor 16 h and then evaporated. The residue was dissolved in water(50 mL) and acidified with conc. HCl and the precipitate was filteredand dried to give benzofuran-4-carboxylic acid (1.83 g,99%). 1H NMR (DMSO d6) d 13.10 (s, 1H), 8.14 (d, J = 2.1 Hz, 1H),7.85-7.91 (m, 2H), 7.43 (t, J = 7.9 Hz, 1H), 7.33 (dd, J = 2.1, 1.0 Hz,1H). Found: [MH] = 161.1.

Reference： [1]Patent: WO2017/155909,2017,A1 .Location in patent: Paragraph 0190
[2]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 1797 - 1809
[3]Journal of Medicinal Chemistry,1995,vol. 38,p. 3094 - 3105

2
[ 166599-84-4 ]
[ 380899-56-9 ]

Yield	Reaction Conditions	Operation in experiment
	With oxalyl dichloride;N,N-dimethyl-formamide; In dichloromethane; at 19 - 20℃; for 2.5h;	All volumes and weights refer to the weight of Intermediate 12. The reactor was charged with Intermediate 1 1 (1.0 eq) and DMF (0.025 vol, 0.14 eq) in dichloromethane (1.9 vol) at 20 0C. A solution of oxalyl chloride (0.20 vol, 1.0 eq) in dichloromethane (2.1 vol) was added at 20-19 0C over 30 minutes. The mixture was stirred 2 hours at 19-20 0C. Solvent (2.8 vol) was removed at a maximum jacket temperature of 45 0C under reduced pressure. The solution was stored under nitrogen in a feed tank. The reactor was cleaned, dried under vacuum and charged with Intermediate 12 (1.0 eq, 1 wt) and dichloromethane (7.0 vol). Trifluoroacetic acid (3.05 wt, 12 eq) was added at 19-20 0C over 18 minutes. The mixture was stirred overnight at 20-21 0C. The mixture was split in 2 equal portions. Each portion was washed with half saturated aqueous Na2CO3 (8.6 vol) at 20 0C. The combined organic phases were dried over MgSO4 (0.45 wt). After filtration the filtrate was transferred into the cleaned and dried reactor. Dichloromethane (1.3 vol) and triethylamine (0.96 vol, 3eq) were added.The acid chloride solution was added at 1-5 0C over 25 minutes and the mixture was stirred at 19-22 0C overnight. The mixture was split in 2 equal portions. Each portion was washed with saturated aqueous NaHCO3 (7.3 vol) at 20 0C. The combined organic phases were concentrated in the cleaned reactor. The mixture was filtered through a plug of silica gel (0.78 wt) conditioned with ethyl acetate and eluted with ethyl acetate (8.8 vol). The filtrate was concentrated in the cleaned reactor and a solvent change to iPrOAc was performed. The resulting suspension was heated to obtain a clear solution. The solution was cooled and seed crystals (obtained by cooling of about 1 vol% of the clear solution) was added at 57C. The resulting suspension was concentrated, cooled to 100C, stirred overnight and filtered. The filter cake was washed with iPrOAc and IPA and dried at a max. jacket temperature of 50 0C and reduced pressure at the rotavap to give intermediate grade title compound. Yield (% theory): 48%
	With thionyl chloride; for 2h;Heating / reflux;	A mixture of <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> [Eissenstat, et al., J. Medicinal Chemistry, 38 (16) 3094-3105 (1995)] (2.8 g, 17.4 mmol) and thionyl chloride (25 mL) was heated to reflux for 2 h and then concentrated in vacuo. The solid residue was dissolved in ethyl acetate (50 mL) and a solution of N,O-dimethylhydroxylamine hydrochloride (2.8 g) in saturated NaHCO3 (60 mL) was added with stirring. After stirring for 1.5 h, the ethyl acetate layer was separated. The aqueous layer was extracted with ethyl acetate. The ethyl acetate extracts were combined, washed with saturated NaHCO3 and concentrated in vacuo to give an oil (3.2 g, 95.4%).

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 3094 - 3105
[2]Patent: WO2009/34133,2009,A1 .Location in patent: Page/Page column 20
[3]Bioorganic and Medicinal Chemistry Letters,2011,vol. 21,p. 5562 - 5567
[4]Patent: EP1027043,2004,B1 .Location in patent: Page/Page column 16

3
[ 166599-84-4 ]
[ 75-65-0 ]
[ 412336-05-1 ]

Reference： [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 871 - 887

4
(1R*,2S*,5S*)-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester [ No CAS ]
[ 166599-84-4 ]
(1R*,2S*,5S*)-2-[(benzofuran-4-carbonyl)-amino]-methyl}-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; for 0.166667h;	A.9 Synthesis of N-substituted (IR ,2S ,5S )-2-(amino-methyl)-3-aza- bicyclo [3.1.0] -hexane derivativesA.9.1 Synthesis of (lR,2S,5S*)-2-(aroylamino-methyl)-3-aza-bicyclo[3.1.0]- hexane-3-carboxylic acid tert-butyl ester derivatives (general procedure); To a solution of the respective carboxylic acid (3.2 mmol, l.lOeq) in DMF (5.0 mL) is added successively DIPEA (8.8 mmol, 3.0eq) and a solution of TBTU (3.7 mmol,1.25eq) in DMF (5.0 mL). The obtained mixture is added to a solution of(IR ,2S ,5S )-2-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (2.9 mmol, l.Oeq) in DMF (5.0 mL). After 10 min sat. aq. NaHCO3 solution and ether are added, the layers are separated and the organic layer is washed with sat. NaHCO3 solution, citric acid (5% in water) and water. After drying over Na2SO4 and removal of solvents in vacuo the desired amides are obtained which are used without further purification.

Reference： [1]Patent: WO2008/38251,2008,A2 .Location in patent: Page/Page column 98

5
[ 166599-84-4 ]
[ 412336-07-3 ]

Reference： [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 871 - 887

6
[ 166599-84-4 ]
4-(4-benzofuranylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 871 - 887

7
[ 79250-46-7 ]
[ 166599-84-4 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 3094 - 3105

8
[ 79950-39-3 ]
[ 166599-84-4 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 3094 - 3105

9
[ 166599-84-4 ]
Benzofuran-4-yl-[1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl]-methanone [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 3094 - 3105

10
[ 166599-85-5 ]
[ 166599-84-4 ]

Yield	Reaction Conditions	Operation in experiment
62%		A solution of Intermediate 10 in toluene (1 wt in 6.6 vol) was added to a refluxing mixture of p-toluenesulfonic acid (0.03 eq., 0.03 wt) in toluene (3.8 vol) over 43 minutes. The mixture was stirred under reflux for 33 minutes then solvent (1.1 vol) was withdrawn at 130 0C jacket temperature under slightly reduced pressure (1000- 880 mbar). The mixture was further stirred at reflux. 4.25 hours after the addition of Intermediate 10 the mixture was cooled to 25 0C. The mixture was filtered over silica gel (1.1 wt) that had been conditioned with toluene (4.1 vol). The silica plug was further washed with toluene (8.2 vol). The product containing fractions were combined (total volume 10.8 vol). Solvent (8.6 vol) was withdrawn at 80 0C jacket temperature under reduced pressure. Toluene (0.6 vol) and 1.0 M NaOH (1.5 eq., 7.7 vol) was added and the two-phase mixture was stirred at 60 0C for 9 hours. After cooling to 20 0C the phases were separated and 32% HCI (1.7 vol) was added at 2- 14C to the aqueous phase. After addition of 9.4 vol toluene the mixture was stirred under reflux for 14.5 hours. The suspension was cooled to 20 0C and THF (5.3 vol) was added. The phases were separated and the organic layer was washed two times with a mixture of 5.6 vol water and 0.6 vol THF. 10.3 vol of solvent was distilled off at 80 0C jacket temperature and reduced pressure before 3.2 vol toluene was added. The mixture was refluxed for 33 minutes (ambient pressure), cooled to 0 0C over 3 hours and stirred at that temperature for 2.5 days. The precipitate was filtered, dried for 2 hours in a stream of nitrogen and dried in a rotavap at 50 0C to give the title compound as an off-white solid. Yield (% theory): 62%

Reference： [1]Patent: WO2009/34133,2009,A1 .Location in patent: Page/Page column 18
[2]Journal of Medicinal Chemistry,1995,vol. 38,p. 3094 - 3105

11
[ 166599-84-4 ]
[ 209256-40-6 ]

Yield	Reaction Conditions	Operation in experiment
83%	With hydrogen;palladium 10% on activated carbon; In acetic acid; under 3102.97 Torr; for 12h;	Benzofuran-4-carboxylic acid [] [Eissenstat, et al, J. Medicinal Chemistry, 38 (16) 3094-3105 (1995)] (10.0 g, 61.7 mmol) was hydrogenated (60 psi) in acetic acid (100 mL) over 10% Pd/C (2 g) for 12 hr. The mixture was filtered and the filtrate was diluted with water (500 mL) to give 2,3-dihydro<strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> as a white powder (8.4 g, 83%). A sample was recrystallized from isopropanol to give fine white needles (mp: 185.5-185.5C).
	With hydrogen;palladium 10% on activated carbon; In ethanol; at 20℃; under 3000.3 Torr; for 16h;	Benzofuran-4-carboxylic acid (30.8 mmol, M.A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105) is added to a suspension of Pd/C (10%, 2.00 g) in EtOH (25 mL). Additional EtOH (75 mL) is added and the mixture is stirred at RT under a hydrogen atmosphere (4 bar) for 16 h. After filtration through celite and removal of the solvents the desired product is obtained which is used without further purification. 1H-NMR (DMSO-dbeta): delta = 3.45 (t, J = 8.79 Hz, 2H); 4.55 (t, J = 8.79 Hz, 2H); 6.99 (d, J = 7.78 Hz, IH); 7.21 (t, J = 7.91 Hz, IH); 7.39 (d, J = 7.78 Hz, IH); 12.9 (bs, IH).
	With hydrogen;palladium 10% on activated carbon; In ethanol; at 20℃; under 3000.3 Torr; for 16h;	Benzofuran-4-carboxylic acid (30.8 mmol, M.A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105) is added to a suspension of Pd/C (10%, 2.00 g) in EtOH (25 mL). Additional EtOH (75 mL) is added and the mixture is stirred at RT under a hydrogen atmosphere (4 bar) for 16 h. After filtration through celite and removal of the solvents the desired product is obtained which is used without further purification. 1H-NMR (DMSO-d6): delta = 3.45 (t, J = 8.79 Hz, 2H); 4.55 (t, J = 8.79 Hz, 2H); 6.99 (d, J = 7.78 Hz, IH); 7.21 (t, J = 7.91 Hz, IH); 7.39 (d, J = 7.78 Hz, IH); 12.9 (bs, IH).

	With hydrogen;palladium 10% on activated carbon; In ethanol; at 20℃; under 3000.3 Torr; for 16h;	Benzofuran-4-carboxylic acid (30.8 mmol, M.A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105) is added to a suspension of Pd/C (10%, 2.00 g) in EtOH (25 mL). Additional EtOH (75 mL) is added and the mixture is stirred at RT under a hydrogen atmosphere (4 bar) for 16 h. After filtration through celite and removal of the solvents the desired product is obtained which is used without further purification. 1H-NMR (DMSO-de): delta = 3.45 (t, J = 8.79 Hz, 2H); 4.55 (t, J = 8.79 Hz, 2H); 6.99 (d, J = 7.78 Hz, IH); 7.21 (t, J = 7.91 Hz, IH); 7.39 (d, J = 7.78 Hz, IH); 12.9 (bs, IH).
	With hydrogen;palladium 10% on activated carbon; In ethanol; at 20℃; under 3000.3 Torr; for 16h;	Benzofuran-4-carboxylic acid (30.8 mmol, M. A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105) is added to a suspension of Pd/C (10%, 2.00 g) in EtOH (25 mL). Additional EtOH (75 mL) is added and the mixture is stirred at RT under a hydrogen atmosphere (4 bar) for 16 h. After filtration through celite and removal of the solvents the desired product is obtained which is used without further purification. 1H-NMR (DMSO-d6): delta=3.45 (t, J=8.79 Hz, 2H); 4.55 (t, J=8.79 Hz, 2H); 6.99 (d, J=7.78 Hz, 1H); 7.21 (t, J=7.91 Hz, 1H); 7.39 (d, J=7.78 Hz, 1H); 12.9 (bs, 1H).
	With hydrogen;palladium 10% on activated carbon; In ethanol; at 20℃; under 3000.3 Torr; for 16h;	A.2 Synthesis of 2,3-dihydro-<strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> Benzofuran-4-carboxylic acid (30.8 mmol, M. A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105) is added to a suspension of Pd/C (10%, 2.00 g) in EtOH (25 mL). Additional EtOH (75 mL) is added and the mixture is stirred at RT under a hydrogen atmosphere (4 bar) for 16 h. After filtration through celite and removal of the solvents the desired product is obtained which is used without further purification. 1H-NMR (DMSO-d6): delta=3.45 (t, J=8.79 Hz, 2H); 4.55 (t, J=8.79 Hz, 2H); 6.99 (d, J=7.78 Hz, 1H); 7.21 (t, J=7.91 Hz, 1H); 7.39 (d, J=7.78 Hz, 1H); 12.9 (bs, 1H).
	With hydrogen;palladium 10% on activated carbon; In acetic acid; under 3102.97 Torr; for 12h;	Benzofuran-4-carboxylic acid (10.0 g, 61.7 mmol) was hydrogenated (60 psi) in acetic acid (100 mL) over 10% Pd/C (2 g) for 12 hr. The mixture was filtered and the filtrate was diluted with water (500 mL) to give 2,3-dihydro<strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> as a white powder (8.4 g, 83%). A sample was recrystallized from isopropanol to give fine white needles (mp: 185.5-187.5C).
	With palladium 10% on activated carbon; hydrogen; In methanol; at 25℃; under 2585.81 Torr; for 12h;	A third exemplary Intermediate B, Intermediate B-3, may be used to synthesize compounds of formula I wherein Z is O, n is one, X is C(R5)2, - is a single bond and one R3 is chlorine. To a solution of <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (900 mg, 5.55 mmol, 1 equiv) in MeOH (9.00 mL) was added palladium on activated carbon (20.0 mg, 555 pmol, 10.0 wt %, 0.10 equiv) under nitrogen. The vessel was evacuated and purged with hydrogen several times. The mixture was stirred at 25 C for 12 h under hydrogen (50.0 psi). The reaction mixture was filtered and the filtrate was concentrated in vacuo to afford 2, 3-dihydro<strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (750 mg, 3.66 mmol, 65.9% yield, 80.0% purity) as a white solid. 1H NMR (400MHz, DMSO-d6) d = 7.38 (d, J=8.0 Hz, 1H), 7.20 (t, =8.0 Hz, 1H), 6.97 (d, =8.0 Hz, 1H), 4.54 (t, =8.8 Hz, 2H), 3.45 (br t, =8.8 Hz, 2H).

Reference： [1]Patent: EP1041980,2005,B1 .Location in patent: Page/Page column 16-17
[2]Patent: WO2008/81399,2008,A2 .Location in patent: Page/Page column 76
[3]Patent: WO2009/16560,2009,A2 .Location in patent: Page/Page column 75
[4]Patent: WO2009/16564,2009,A2 .Location in patent: Page/Page column 30
[5]Patent: US2010/16401,2010,A1 .Location in patent: Page/Page column 39
[6]Patent: US2011/9461,2011,A1 .Location in patent: Page/Page column 15
[7]Patent: EP1027043,2004,B1 .Location in patent: Page/Page column 16
[8]Patent: WO2019/152419,2019,A1 .Location in patent: Paragraph 0171-0172

12
[ 79950-39-3 ]
[ 166599-84-4 ]
[ 412336-05-1 ]

Yield	Reaction Conditions	Operation in experiment
	With diphenylphosphoranyl azide; triethylamine; In tert-butyl alcohol;	Using analogous procedures to those described in J. Med. Chem., 1995, 38, 3102-3103, methyl 2-allyl-3-hydroxybenzoate was converted in three steps via methyl 2-hydroxy-2,3-dihydrobenzofuran-4-carboxylate and methyl benzofuran-4-carboxylate into <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong>. A mixture of benzofuran-4carboxylic acid (0.5 g), diphenylphosphoryl azide (1.2 ml), triethylamine (0.79 ml) and tert-butanol (1.5 ml) were stirred and heated to reflux for 18 hours. The mixture was cooled to ambient temperature and partitioned between ethyl acetate and water. The organic phase was washed in turn with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography using methylene chloride as eluent. There was thus obtained tert-butyl benzofuran-4-carbamate (0.8 g) as an oil; Mass Spectrum: M+Na+ 256.

Reference： [1]Patent: US2004/44015,2004,A1

13
[ 188111-79-7 ]
[ 166599-84-4 ]
[ 1030389-11-7 ]

Yield	Reaction Conditions	Operation in experiment
82%	With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 20h;	A.2.4 Synthesis of (R)-3-[(benzofuran-4-carbonyl)-amino]-piperidine-l- carboxylic acid tert-buty ester; A mixture of (R)-3-amino-l-N-Boc-piperidine (1 g), <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (809 mg), PyBOP (2.6g), DIEA (1.96 mL) in dry DMF (10 mL) was stirred at RT under nitrogen for 20 h. The reaction mixture was diluted with EA, washed with water. The aqueous phase was extracted twice with EA, the combined organic extracts were washed with brine, dried (MgSO4), filtered and concentrated to yield a crude light brown oil. FC (EA/ n-heptane: 1/1 to EA) gave 1.41 g (82%) of the title compound as an oil. LC-MS: tR = 0.93 min; [M+H]+ = 345.
82%	With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 20h;	A mixture of (R)-3-amino-1-N-Boc-piperidine (1 g), <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (809 mg), PyBOP (2.6 g), DIEA (1.96 mL) in dry DMF (10 mL) was stirred at RT under nitrogen for 20 h. The reaction mixture was diluted with EA, washed with water. The aqueous phase was extracted twice with EA, the combined organic extracts were washed with brine, dried (MgSO4), filtered and concentrated to yield a crude light brown oil. FC (EA/n-heptane: 1/1 to EA) gave 1.41 g (82%) of the title compound as an oil.LC-MS: tR=0.93 min; [M+H]+=345.

Reference： [1]Patent: WO2008/65626,2008,A2 .Location in patent: Page/Page column 26
[2]Patent: US2010/69418,2010,A1 .Location in patent: Page/Page column 13

14
[ 1038509-56-6 ]
[ 166599-84-4 ]
[ 1038509-59-9 ]

Yield	Reaction Conditions	Operation in experiment
	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; for 2h;	TBTU (1.24 mmol, 1.05eq) is added to a solution of the respective carboxylic acid (1.18 mmol, l.Oeq), (lS,3S,5S)-3-aminomethyl-2-aza-bicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester (1.18 mmol, l.Oeq) and DIPEA (1.77 mmol, 1.5eq) in DCM, DMF or acetonitrile (10 mL). After 2h the mixture is washed with water, hydrochloric acid (0.5 M) and water. The organic layer is dried over Na2SO4, the solvents are removed in vacuo and the residue is purified by prep. HPLC or by flash chromatography (EtO Ac/heptane).(lS,3S,5S)-3-[(benzofuran-4-carbonyl)-amino]-methyl}-2-aza-bicyclo[3.1.0]hexane-2- carboxylic acid tert-butyl ester prepared by reaction of (lS,3S,5S)-3-aminomethyl-2-aza-bicyclo[3.1.0]hexane-2- carboxylic acid tert-butyl ester with <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (M.A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105). LC-MS (acidic): tR = 1.00 min; [M+H]+ = 357.1. 1H- NMR (CDCl3): delta = 0.58 (bs, IH); 0.80-0.86 (m, IH); 1.52 (s, 9H); 1.52-1.59 (m, IH); 1.79 (bd, J = 13.3 Hz, IH); 2.51-2.60 (m, IH); 3.24-3.30 (m, IH); 3.60-3.64 (m, 2H); 4.45-4.52 (m, IH); 7.32 (t, J = 7.9 Hz, IH); 7.47 (bs, IH); 7.61 (d, J = 8.2 Hz, IH); 7.65 (d, J = 7.5 Hz, IH); 7.70 (bs, IH); 8.43 (bs, IH).

Reference： [1]Patent: WO2008/81399,2008,A2 .Location in patent: Page/Page column 87

15
[ 1108172-95-7 ]
[ 166599-84-4 ]
[ 1108172-98-0 ]

Yield	Reaction Conditions	Operation in experiment
		To a solution of the respective carboxylic acid (0.85 mmol) in DMF (4.0 mL) is added successively DIPEA (2.40 mmol) and TBTU (0.97 mmol). The obtained mixture is stirred for 10 min and treated with a solution of (lS,2S,5R)-2-Aminomethyl-3-aza- bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (0.84 mmol) in DMF (1.5 mL). After LC-MS indicated complete conversion (10 min - 16 h) sat. aq. NaHCOs solution and ether (50 mL) are added, the layers are separated and the aq. layer is extracted twice with ether. The combined organic layers are washed twice with sat. NaHCC>3 solution, twice with citric acid (5% in water) and once with brine. After drying over MgSO4 and removal of solvents in vacuo the respective amide is obtained which is either purified by FC (EtO Ac/heptane) or used without further purification.; (lS,2S,5R)-2-[(Benzofuran-4-carbonyl)-amino]-methyl}-3-aza- bicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (method A) prepared by reaction of (lS,2S,5R)-2-Aminomethyl-3-aza-bicyclo[3.1.0]hexane- 3-carboxylic acid tert-butyl ester with <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (M.A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105). LC-MS (basic): tR = 0.91 min; [M+H]+ = 357.2.

Reference： [1]Patent: WO2009/16560,2009,A2 .Location in patent: Page/Page column 93-94

16
[ 1117693-67-0 ]
[ 166599-84-4 ]
[ 1117693-63-6 ]

Yield	Reaction Conditions	Operation in experiment
22%	With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide;	(RS)-2-Cyclopropyl-2-[methyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl- ammonium chloride (0.17 mmol, 1.0 eq.) was suspended in DMF (0.2 ml) and a solution of <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (0.135 mmol, 0.79 eq.) and DIPEA (0.57 mmol, 3.4 eq.) in DMF (0.54 ml) was added. Finally a solution of HATU (0.135 ml, 0.79 eq.) was added and the mixture was shaken overnight. The solvent was stripped off and the residue was purified by preparative HPLC yielding the desired product (0.0134 g, 22%)LC-MS: tR = 0.99; [M+H]+ = 460.18

Reference： [1]Patent: WO2009/22311,2009,A2 .Location in patent: Page/Page column 64-65

17
[ 1181573-42-1 ]
[ 166599-84-4 ]
[ 1181573-44-3 ]

Yield	Reaction Conditions	Operation in experiment
		B.2 Synthesis of (lR^S^SJ-S-Acylaminomethyl-l-aza-bicyclobeta.l.ljheptane derivatives; B.2.1 Synthesis of (lR^S^SJ-S-Acylaminomethyl^-aza-bicyclobetaJ.llheptane^- carboxylic acid tert-butyl ester derivatives; (general procedure); TBTU (0.73 mmol, 1.1 Oeq) is added to a solution of the respective carboxylic acid (0.70 mmol, 1.05eq) and DIPEA (1.66 mmol, 2.5eq) in DCM (1.0 mL) and DMF (0.25 mL). After 10 min a solution of (lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]heptane-2- carboxylic acid tert-butyl ester (0.66 mmol, l.Oeq) in DCM (1.0 mL) is added and the mixture is stirred for 2h and washed twice with water (1.0 mL). The organic layer is dried over MgSO4, the solvents are removed in vacuo and the residue is purified by prep. HPLC to give the respective amide.; (lR,3S,4S)-3-[(Benzofuran-4-carbonyl)-amino]-methyl}-2-aza-bicyclo[2.2.1]heptane- 2-carboxylic acid tert-butyl ester prepared by reaction of (lR,3S,4S)-3-aminomethyl-2-aza-bicyclo[2.2.1]heptane-2- carboxylic acid tert-butyl ester with <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (M.A. Eissenstat et al. J. Med. Chem. 1995, 38, 3094-3105). LC-MS (basic): tR = 0.97 min; [M+H]+ = 371.1.

Reference： [1]Patent: WO2009/104155,2009,A1 .Location in patent: Page/Page column 62

18
[ 166599-84-4 ]
[ 1061591-03-4 ]

Yield	Reaction Conditions	Operation in experiment
23%		a) 2-Iodo-<strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> To a cold (-78 C.) solution of <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (100 mg) in dry diethyl ether (1.2 mL), was added dropwise tert-butyl lithium (1.7 M in pentane, 0.8 mL, 2.2 eq). The reaction mixture was stirred at -78 C. for 30 min. under nitrogen, then a solution of iodine (172.2 mg, 1.2 eq) in ether (1.9 mL) was added dropwise. The reaction was stirred at -78 C. for 30 min. and allowed to warm to rt. The reaction mixture was partitioned between sat. NH4Cl and diethyl ether, the aqueous phase was extracted once again with diethyl ether. The combined organic extracts were washed with sat. sodium thiosulfate, water, dried (Na2SO4), filtered and concentrated to yield a crude brown solid. FC (DCM/MeOH: 99/1 to 97/3) afforded the title compound as a pink solid (40 mg, 23%). LC-MS: tR=0.89 min; [m+H]+=288.99.

Reference： [1]Patent: US2010/113531,2010,A1 .Location in patent: Page/Page column 34

19
[ 391248-13-8 ]
[ 166599-84-4 ]
[ 1061591-40-9 ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane;	A.4.1 Synthesis of 4-[acyl-amino]-methyl}-thiazolidine-3-carboxylic acid tert-butyl ester Derivatives (General Procedure)To a solution of the respective carboxylic acid R1COOH, wherein R1 is as defined for formula (I), (4.6 mmol, 1.0 eq.), 4-aminomethyl-thiazolidine-3-carboxylic acid tert-butyl ester (4.6 mmol, 1.0 eq.) and DMAP (2.3 mmol, 1.0 eq.) in DCM (25 mL) was added under stirring solid EDC (4.7 mmol, 1.02 eq.). Stirring continued over night. Then sat. aq. NaHCO3 solution (6 mL) was added to the reaction mixture and stirring continued for 30 min. The organic phase was separated, the solvent was stripped off yielding the crude corresponding 4-[acyl-amino]-methyl}-thiazolidine-3-carboxylic acid tert-butyl ester derivative.

Reference： [1]Patent: US2010/113531,2010,A1 .Location in patent: Page/Page column 25

20
[ 1007873-74-6 ]
[ 166599-84-4 ]
[ 1007873-72-4 ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 20h;	To a mixture of <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (Eissenstat M. A. et al, J. Med. Chem. 1995, 38, 16, 3094-3105 (61 mg), PyBOP (196 mg), DIEA (0.15 mL) in dry DMF (0.5 mL), was added a solution of (2RS)-(2-aminomethyl-azetidin-1-yl)-biphenyl-2-yl-methanone (100 mg) in dry DMF (0.5 mL). The resulting reaction mixture was stirred at RT for 20 h. The reaction mixture was diluted with EA, washed with water. The aqueous phase was extracted once again with EA, the combined organic extracts were dried (MgSO4), filtered and concentrated to yield the crude product as light brown oil.FC (EA) gave 140 mg (71%) of the title compound as a light yellow oilLC-MS: rt=0.99 min, 411 [M+H]+.

Reference： [1]Patent: US2010/222600,2010,A1 .Location in patent: Page/Page column 22

21
[ 1007873-82-6 ]
[ 166599-84-4 ]
[ 1007873-83-7 ]

Yield	Reaction Conditions	Operation in experiment
78%	With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 20h;	To a mixture of <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (11 mg), PyBOP (35 mg), DIEA (0.030 mL) in dry DMF (0.15 mL), was added a solution of (2RS)-(2-aminomethyl-azetidin-1-yl)45-(4-fluoro-phenyl)-2-methyl-thiazol-4-A-methanone (20 mg) in dry DMF (0.1 mL). The resulting reaction mixture was stirred at RT for 20 h. The reaction mixture was diluted with EA, washed with water. The aqueous phase was extracted once again with EA, the combined organic extracts were dried (MgSO4), filtered and concentrated to yield a crude light brown oil.FC (EA to DCM/MeOH: 98/2) gave 23 mg (78%) of the title compound as a white solid.LC-MS: rt=0.94 min, 450 [M+H]+.

Reference： [1]Patent: US2010/222600,2010,A1 .Location in patent: Page/Page column 23

22
[ 1007873-90-6 ]
[ 166599-84-4 ]
[ 1007873-91-7 ]

Yield	Reaction Conditions	Operation in experiment
30%	With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide;Inert atmosphere;	To a solution of <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (548.5 mg), TBTU (1.41 g) DIEA (1.73 mL) in dry DMF (6 mL) was added dropwise a solution of (2S)-aminomethyl-azetidine-1-carboxylic acid tert-butyl ester (630 mg) in dry DMF (2 mL). The reaction mixture was stirred under nitrogen for 72 h. The reaction mixture was diluted with EA, washed with water, the aqueous phase was extracted twice again with EA. The combined organic extracts were washed with brine, dried (Na2SO4), filtered and concentrated to yield a crude oil.FC (EA/n-heptane: 1/1) gave 336 mg (30%) of the title compound as a white solid.LC-MS: rt=0.95 min, 331 [M+H]+.

Reference： [1]Patent: US2010/222600,2010,A1 .Location in patent: Page/Page column 24

23
[ 1007873-77-9 ]
[ 166599-84-4 ]
[ 1007873-75-7 ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 20h;	To a mixture of <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (Eissenstat M. A. et al, J. Med. Chem. 1995, 38, 16, 3094-3105 (63.3 mg), PyBOP (203 mg), DIEA (0.116 mL) in dry DMF (1.5 mL), was added a solution of (2RS)-[1-(biphenyl-2-sulfonyl)-azetidin-2-yl]-methylamine (118 mg) in dry DMF (0.5 mL). The resulting reaction mixture was stirred at RT for 20 h. The reaction mixture was diluted with EA, washed with water. The aqueous phase was extracted once again with EA, the combined organic extracts were dried (MgSO4), filtered and concentrated to yield the crude product as light brown oil.FC (EA) gave 118 mg (67%) of the title compound as a light yellow oil.LC-MS: rt=1.04 min, 447 [M+H]+.

Reference： [1]Patent: US2010/222600,2010,A1 .Location in patent: Page/Page column 22

24
[ 1238071-95-8 ]
[ 166599-84-4 ]
[ 1312557-94-0 ]

Yield	Reaction Conditions	Operation in experiment
78%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In dichloromethane; at 20℃; for 20h;	b Benzofuran-4-carboxylic acid ((S)-1-benzyl-2-cyano-ethyl)-methyl-amide(S)-3-Methylamino-4-phenyl-butyronitrile hydrochloride (2.2 g, 10.4 mmol), benzofuran-4- carboxylic acid (2.03 g, 12.5 mmol), HOBt (1.9 g, 12.5 mmol), EDC x HCI (3.0 g, 15.7 mmol), and triethylamine (5.82 ml, 41.8 mmol) were dissolved in DCM (50 ml) and the reaction was stirred at rt for 20h. The mixture was diluted with EtOAc, washed with NaHC03- and NaCI- soln., dried (Na2S04), filtered and concentrated. The crude product was purified by chromatography (Flashmaster, Hex to Hex:EtOAc 2:3 over 60 min; Hex:EtOAc 2:3 for 5 min) to yield 2.59 g (78%) of the title compound as yellowish oil. [1 H-NMR (DMSO, 600 MHz, rotamers) 7.97/7.94 (s, 1 H), 7.61/7.58 (d, 1 H), 7.36-6.86 (m, 7H), 6.46/6.16 (s, 1 H), 5.25/4.02 (br s, 1 H), 3.14-2.68 (m, 4H), 3.05/2.61 (s, 3H); LCMS RtA = 2.729 min; [M+H]+ = 319.2].

Reference： [1]Patent: WO2011/73316,2011,A1 .Location in patent: Page/Page column 116

25
(RS)-2-cyclopropyl-2-[methyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)amino]ethyl-ammonium chloride [ No CAS ]
[ 166599-84-4 ]
[ 1117693-63-6 ]

Yield	Reaction Conditions	Operation in experiment
22%	With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide;	(RS)-2-Cyclopropyl-2-[methyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl-ammonium chloride (0.17 mmol, 1.0 eq.) was suspended in DMF (0.2 ml) and a solution of <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (0.135 mmol, 0.79 eq.) and DIPEA (0.57 mmol, 3.4 eq.) in DMF (0.54 ml) was added. Finally a solution of HATU (0.135 ml, 0.79 eq.) was added and the mixture was shaken overnight. The solvent was stripped off and the residue was purified by preparative HPLC yielding the desired product (0.0134 g, 22%) LC-MS: tR=0.99; [M+H]+=460.18

Reference： [1]Patent: US2011/263662,2011,A1 .Location in patent: Page/Page column 29

26
[ 1396788-43-4 ]
[ 166599-84-4 ]
C₂₈H₂₉N₃O₄S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 3890 - 3894

27
C₁₈H₂₂FN₃OS [ No CAS ]
[ 166599-84-4 ]
C₂₇H₂₆FN₃O₃S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 3890 - 3894

28
rac-((2S,3R)-2-(aminomethyl)-3-methylpiperidin-1-yl)(2-methyl-5-phenylthiazol-4-yl)methanone [ No CAS ]
[ 166599-84-4 ]
C₂₇H₂₇N₃O₃S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 3890 - 3894

29
C₁₈H₂₀F₃N₃OS [ No CAS ]
[ 166599-84-4 ]
C₂₇H₂₄F₃N₃O₃S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2012,vol. 22,p. 3890 - 3894

30
[ 166599-84-4 ]
1-(benzofuran-4-ylmethyl)-N₅-cyclopropyl-N₃-methyl-2-oxo-1,2-dihydropyridine-3,5-dicarboxamide [ No CAS ]

Reference： [1]Patent: WO2017/37116,2017,A1

31
[ 166599-84-4 ]
[ 173470-67-2 ]

Yield	Reaction Conditions	Operation in experiment
	With borane-THF; In tetrahydrofuran; at 20℃; for 1h;	To <strong>[166599-84-4]benzofuran-4-carboxylic acid</strong> (50 mg, 0.308 mmol, commercially available from, for example, J&W PharmLab) in THF (1 mL), borane tetrahydrofuran complex (0.47 mL, 1M in THF, 0.470 mmol) was added and the reaction stirred at rt for 1 h. The reaction was quenched with NaHCO3 (20 mL)and extracted with EtOAc (3 x 10 mL). The organic layers were dried over a hydrophobic frit and concentrated to give 50 mg of a colourless oil. This was purified bychromatography on 5i02 (Biotage SNAP 10 g cartridge, eluting with O-5O% EtOAc/cyclohexane), theappropriate fractions were concentrated to give benzofuran-4-ylmethanol (37 mg, 0.225 mmol, 72.9 % yield) as a white solid.LCMS (2 mm Formic): Rt = 0.72 mi [M-OH] = 131.1.

Reference： [1]Patent: WO2017/37116,2017,A1 .Location in patent: Page/Page column 74

32
[ 166599-84-4 ]
4-(bromomethyl)benzofuran [ No CAS ]

Reference： [1]Patent: WO2017/37116,2017,A1

33
[ 6638-79-5 ]
[ 166599-84-4 ]
[ 209256-39-3 ]

Yield	Reaction Conditions	Operation in experiment
93%		Oxalyl chloride (1.14 mL, 13.5 mmol) was added to a suspension of 132 (1.82 g, 11.2 mmol) in DCM (100 mL, anhydrous) and DMF (0.2 mL, 2.5 mmol) at r.t.. The mixture was stirred at r.t. for 1 h to give a colourless solution which was cooled to 0 C. Nu,Omicron- Dimethylhydroxylamine hydrochloride (1.31 g, 13.5 mmol) and pyridine (2.72 mL, 33.6 mmol) were added sequentially and the mixture was stirred at r.t. for 18 h, then partitioned between DCM and water. Column chromatography with 95:5 DGVLEtOAc gave 133 (2.13 g, 93%). 1H MR (CDC13) delta 7.68 (d, J = 2.2 Hz, 1H), 7.59 (dt, J = 8.3, 0.8 Hz, 1H), 7.51 (dd, J = 7.5, 0.9 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 6.95 (dd, J = 2.2, 0.9 Hz, 1H), 3.56 (s, 3H). 3.40 (s, 3H). Found: [M+H]=206.2
93%		Oxalyl chloride (1.14 mL, 13.5 mmol) was added to a suspensionof thew above acid (1.82 g, 11.2 mmol) in DCM (100 mL, anhydrous)and DMF (0.2 mL, 2.5 mmol) at 20 C. The mixture wasstirred at 20 C for 1 h to give a colourless solution which wascooled to 0 C. N,O-Dimethylhydroxylamine hydrochloride (1.31g, 13.5 mmol) and pyridine (2.72 mL, 33.6 mmol) were addedsequentially and the mixture was stirred at 20 C for 18 h, thenpartitioned between DCM and water. Column chromatographywith 95:5 DCM:EtOAc gave N-methoxy-N-methylbenzofuran-4-carboxamide (2.13 g, 93%). 1H NMR (CDCl3) d 7.68 (d, J = 2.2 Hz,1H), 7.59 (dt, J = 8.3, 0.8 Hz, 1H), 7.51 (dd, J = 7.5, 0.9 Hz, 1H),7.32 (t, J = 7.9 Hz, 1H), 6.95 (dd, J = 2.2, 0.9 Hz, 1H), 3.56 (s, 3H).3.40 (s, 3H). Found: [M+H] = 206.2.

Reference： [1]Patent: WO2017/155909,2017,A1 .Location in patent: Paragraph 0191
[2]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 1797 - 1809

34
[ 177734-79-1 ]
[ 166599-84-4 ]

Reference： [1]Patent: WO2017/155909,2017,A1
[2]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 1797 - 1809

35
[ 166599-84-4 ]
1-(benzofuran-4-yl)-3-(dimethylamino)propan-1-one [ No CAS ]

Reference： [1]Patent: WO2017/155909,2017,A1
[2]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 1797 - 1809

36
[ 480-97-7 ]
[ 166599-84-4 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 1797 - 1809

37
[ 166599-84-4 ]
C₃₂H₃₃BrN₂O₅ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 1797 - 1809

38
[ 166599-84-4 ]
C₃₃H₃₅BrN₂O₅ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 1797 - 1809

39
[ 166599-84-4 ]
C₃₄H₃₇BrN₂O₅ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 1797 - 1809

40
[ 166599-84-4 ]
C₃₅H₃₇N₃O₅ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 1797 - 1809

41
[ 166599-84-4 ]
(+/-)-(trans)-N-[[2-(2,3-dihydrobenzofuran-4-yl)cycloprop-1-yl]methyl]acetamide [ No CAS ]